Skip to content

Ki Hyeong Lee

Institut Gustave Roussy

2 papers in the Anchorcite directory, published in 2017, cited 10,355 times in total.

ORCID profile

Research topics

Frequent co-authors

  • Byoung Chul Cho · 2 papers
  • David Planchard · 2 papers
  • Jhanelle E. Gray · 2 papers
  • Jean‐Charles Soria · 1 paper
  • Yuichiro Ohe · 1 paper
  • Johan Vansteenkiste · 1 paper
  • Thanyanan Reungwetwattana · 1 paper
  • Busayamas Chewaskulyong · 1 paper

Papers

  1. Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 5,640 citations

    BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell…

  2. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 4,715 citations

    BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in…

Metadata from OpenAlex (CC0).